급성 허혈성 뇌졸중(AIS)은 2023년 16개 국가에서 90,000,000명 이상이 발병할 것으로 예상되며, 현재 시판 중인 AIS 치료제는 8개 품목에 불과하고, 여러 회사가 다양한 브랜드명으로 판매 중인 알테플라제는 여러 지역에서 판매되고 있습니다. AIS 파이프라인은 매우 견고하며, 1개 약물이 등록 전 단계에 있고 13개 약물이 현재 3상 개발 단계에 있습니다.
지난 10년간 총 662건의 AIS 관련 임상시험이 진행되었습니다. 2021년 100건으로 가장 많았고, 2022년 92건으로 그 뒤를 이었으며, 남미와 아프리카에서는 AIS 자산 개발에서 라이선스 계약이 지배적인 거래 형태로 부상했습니다. 인수 및 파트너십은 유럽, 아시아태평양 및 북미 시장에서 우세했습니다.
이 보고서는 세계 급성 허혈성 뇌졸중(AIS) 시장을 조사하여 질환 개요, 임상시험 동향, 파이프라인 개요, 향후 전망 등을 제공합니다.
목차
제1장 서문
제2장 주요 조사 결과
제3장 질병 상황
제4장 출시 약제 평가
- 주요 출시 약제
- 작용기서별 개요
- 투여 경로별 개요
- 출시 약제 프로파일과 판매량 예측
제5장 약가 설정과 상환 평가
제6장 파이프라인 약제 평가
- 제III상 파이프라인 약제
- 개발 단계별 개요
- 분자 유형별 개요
- 작용기서별 개요
- 투여 경로별 개요
- 의약품 특이적 상전이 성공률(PTSR)과 승인 가능성(LoA)
- 치료 분야 및 적응증 고유의 PTSR 및 LoA
제7장 임상시험 평가
- 역사적 개요
- 상별 개요
- 상황별 개요
- 진행중 및 계획중인 시험의 상별 개요
- 가상 컴포넌트를 사용한 임상시험
- 지역적 개요
- 지역별 단일국 및 다국적 시험
- 상위 20개 스폰서와 상별 내역
- 상위 20개 스폰서 상황별 내역
- 엔드포인트 상황별 개요
- 인종 및 민족별 개요
- 등록 데이터
- 임상시험 사이트 상위 20개국
- 세계의 상위 20개 사이트
- 실현 가능성 분석 - 지역적 개요
- 실현 가능성 분석 - 벤치마크 모델
제8장 거래 상황
제9장 상업적 평가
제10장 향후 시장 성장 촉진요인
제11장 부록
ksm
This reports provides a data-driven overview of the current and future competitive landscape in AIS therapeutics.
- More than 90,000,000 diagnosed prevalent cases of AIS are anticipated in 2023 in the 16 countries covered in GlobalData's epidemiology forecast for AIS.
- There are only eight marketed drugs for AIS, with alteplase being marketed by various companies under various brand names and in multiple geographies.
- The pipeline for AIS is very robust with one drug in pre-registration stage, whereas 13 drugs are currently in Phase III development stage.
- Over the past 10 years, a total of 662 trials have been conducted for AIS. The highest number of trials occurred in 2021, with 100 trials, followed by 2022 with 92 trials.
- In the development of AIS assets, licensing agreements emerged as the dominant deal type in South America and Africa. Acquisitions and partnership displayed prevalence in the markets of Europe, Asia-Pacific, and North America.
Scope
GlobalData's AIS: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the AIS market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AIS market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Table of Contents
1 Preface
- 1.1 Contents
- 1.2 Report Scope
- 1.3 List of Tables and Figures
- 1.4 Abbreviations
2 Key Findings
3 Disease Landscape
- 3.1 Disease Overview
- 3.2 Epidemiology Overview
- 3.3 Treatment Overview
4 Marketed Drugs Assessment
- 4.1 Leading Marketed Drugs
- 4.2 Overview by Mechanism of Action
- 4.3 Overview by Route of Administration
- 4.4 Marketed Drugs Profiles and Sales Forecasts
5 Pricing and Reimbursement Assessment
- 5.1 Annual Therapy Cost
- 5.2 Time to Pricing and Reimbursement
6 Pipeline Drugs Assessment
- 6.1 Phase III Pipeline Drugs
- 6.2 Overview by Development Stage
- 6.3 Overview by Molecule Type
- 6.4 Overview by Mechanism of Action
- 6.5 Overview by Route of Administration
- 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
- 6.7 Therapy Area and Indication-specific PTSR and LoA
7 Clinical Trials Assessment
- 7.1 Historical Overview
- 7.2 Overview by Phase
- 7.3 Overview by Status
- 7.4 Overview by Phase for Ongoing and Planned Trials
- 7.5 Trials with Virtual Components
- 7.6 Geographic Overview
- 7.7 Single-Country and Multinational Trials by Region
- 7.8 Top 20 Sponsors with Breakdown by Phase
- 7.9 Top 20 Sponsors with Breakdown by Status
- 7.10 Overview by Endpoint Status
- 7.11 Overview by Race and Ethnicity
- 7.12 Enrollment Data
- 7.13 Top 20 countries for Trial Sites
- 7.14 Top 20 Sites Globally
- 7.15 Feasibility Analysis - Geographic Overview
- 7.16 Feasibility Analysis - Benchmark Models
8 Deals Landscape
- 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
- 8.2 Recent Mergers, Acquisitions, and Strategic Alliances
9 Commercial Assessment
10 Future Market Catalysts
11 Appendix
- 11.1 Methodology
- 11.2 Methodology - Sales Forecast
- 11.3 Methodology - Pricing and Reimbursement
- 11.4 Methodology - PTSR and LoA Analysis
- 11.5 About the Authors
- 11.6 Contact Us
- 11.7 Disclaimer
